Search
Alterity Therapeutics Ltd
ATHEAdd to Watchlist
5.360USD
-0.100-1.83%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
81.54MMarket Cap
LossP/E TTM
More Details of Alterity Therapeutics Ltd Company
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Alterity Therapeutics Ltd Info
Ticker SymbolATHE
Company nameAlterity Therapeutics Ltd
IPO dateMar 28, 2000
CEOStamler (David A)
Number of employees9
Security typeDepository Receipt
Fiscal year-endMar 28
AddressLevel 14, 350 Collins Street
CityMELBOURNE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryAustralia
Postal code3000
Phone61393494906
Websitehttps://alteritytherapeutics.com/
Ticker SymbolATHE
IPO dateMar 28, 2000
CEOStamler (David A)
Company Executives of Alterity Therapeutics Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Julian Barbaczy
Mr. Julian Barbaczy
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Julian Barbaczy
Mr. Julian Barbaczy
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
FAQs
Who are the top five shareholders of Alterity Therapeutics Ltd?
The top five shareholders of Alterity Therapeutics Ltd are: Mr. Peter Ashley Marks
How many institutions hold shares of Alterity Therapeutics Ltd (ATHE)?
As of 2026Q1, 32 institutions hold shares of Alterity Therapeutics Ltd, with a combined market value of approximately 327.31K, accounting for 1.81% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -185355.00.